On Tuesday, Verve Therapeutics Inc (NASDAQ: VERV) was -3.43% drop from the session before settling in for the closing price of $7.28. A 52-week range for VERV has been $4.30 – $19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 126.44%. When this article was written, the company’s average yearly earnings per share was at 22.12%. With a float of $63.10 million, this company’s outstanding shares have now reached $84.64 million.
Let’s determine the extent of company efficiency that accounts for 255 employees. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verve Therapeutics Inc stocks. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 73.27%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.28% during the next five years compared to -67.06% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
You can see what Verve Therapeutics Inc (VERV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 13.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.81 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 1.21 million, which is a drop from its year-to-date volume of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 13.94%. Additionally, its Average True Range was 0.68.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 53.90%, which indicates a significant increase from 9.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.24% in the past 14 days, which was lower than the 94.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.80, while its 200-day Moving Average is $5.94. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $7.33. Second resistance stands at $7.63. The third major resistance level sits at $7.90. If the price goes on to break the first support level at $6.76, it is likely to go to the next support level at $6.49. Should the price break the second support level, the third support level stands at $6.19.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are 84,664K outstanding shares of the company, which has a market capitalization of 595.19 million. As of now, sales total 11,760 K while income totals -200,070 K. Its latest quarter income was 6,870 K while its last quarter net income were -50,130 K.
